Sunil Kapur, MD
Cardiovascular Disease · Boston, MANPI 1144458399
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 35.9% of the total. 2025 is the largest year on record at $320,061, more than ten times the $21,971 reported in 2019. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,062 payments — averaging $774.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$295K
- Boston Scientific$275K
- Elutia, Inc.$103K
- Biotronik Inc.$66K
- Medtronic$50K
- Philips North America LLC$10K
- plus $24K from 15 others
Across 69 payments — averaging $2723.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$87K
- Elutia, Inc.$61K
- Novartis$16K
- Boston Scientific$15K
- Biotronik Inc.$10K
- Medtronic$475
What the payments were for
- Consulting fees$315,22338%
- Speaking & faculty fees$428,49352%
- Travel & lodging$54,4587%
- Food & beverage$24,2053%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 385 | $295,024 |
| Boston Scientific | 284 | $274,536 |
| Elutia, Inc. | 47 | $102,694 |
| Biotronik Inc. | 152 | $66,375 |
| Medtronic(2 entities) | 140 | $49,803 |
| Philips North America LLC | 10 | $9,847 |
| Merit Medical Systems Inc | 5 | $7,543 |
| Pfizer | 6 | $5,985 |
| Biosense Webster, Inc. | 14 | $4,846 |
| Atricure, Inc. | 1 | $2,000 |
| ZOLL Medical Corporation | 2 | $1,235 |
| BD | 1 | $982 |
| Medical Device Business Services, Inc. | 1 | $675 |
| Pacira Pharmaceuticals Incorporated | 1 | $273 |
| Cordis US CORP. | 3 | $203 |
| ZOLL Respicardia, Inc. | 1 | $181 |
| Impulse Dynamics (USA) Inc. | 1 | $159 |
| Cardiva Medical, Inc. | 3 | $91 |
| Amgen | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Davol Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ECM Patch,Pouch$102,464
- EMBLEM MRI S-ICD$74,337
- GENERAL EP$72,188
- ADVISOR$59,650
- ENSITE$58,989
- Ensite Cardiac Mapping System$38,707
- GENERAL - THERAPIES$31,824
- ALLURE$18,800
- Micra$16,048
- ENSITE PRECISION$14,901
- VersaCross Large Access Solution$14,565
- Farapulse$14,433
- Accent Pacemaker$13,800
- Advisor Catheter$13,106
- AVEIR$12,524
- ALLURE QUADRA$10,104
- (9520) IGT Devices Undivided$9,561
- Allure CRT Pacemaker$9,469
- WATCHMAN Access System$9,353
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$9,350
How this compares
$822,547 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $21,471 |
| Metoprolol Succinate | 22 | $478 |
| SotalolSotalol Hcl | 11 | $126 |
| Atorvastatin Calcium | 11 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,985 | $21,47118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
- Jorge PlutzkyBoston$528K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.